Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Liabilities and Shareholders Equity (2018 - 2025)

BioNexus Gene Lab's Liabilities and Shareholders Equity history spans 8 years, with the latest figure at $7.6 million for Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity fell 30.68% year-over-year to $7.6 million; the TTM value through Sep 2025 reached $37.0 million, down 17.32%, while the annual FY2024 figure was $10.4 million, 8.47% down from the prior year.
  • Liabilities and Shareholders Equity for Q3 2025 was $7.6 million at BioNexus Gene Lab, down from $9.4 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $11.5 million in Q3 2023 and bottomed at $7.6 million in Q3 2025.
  • The 5-year median for Liabilities and Shareholders Equity is $9.5 million (2025), against an average of $9.6 million.
  • The largest annual shift saw Liabilities and Shareholders Equity soared 863.76% in 2021 before it crashed 30.68% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $9.6 million in 2021, then decreased by 8.71% to $8.7 million in 2022, then surged by 30.43% to $11.4 million in 2023, then decreased by 8.47% to $10.4 million in 2024, then fell by 26.96% to $7.6 million in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Liabilities and Shareholders Equity are $7.6 million (Q3 2025), $9.4 million (Q2 2025), and $9.5 million (Q1 2025).